- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 390563, 7 pages
Assessment of T Regulatory Cells and Expanded Profiling of Autoantibodies May Offer Novel Biomarkers for the Clinical Management of Systemic Sclerosis and Undifferentiated Connective Tissue Disease
1Clinical Pathology and Microbiology, San Gallicano Dermatology Institute, Via Elio Chianesi 53, 00144 Rome, Italy
2Clinical Dermatology, San Gallicano Dermatology Institute, Via Elio Chianesi 53, 00144 Rome, Italy
3Biostatistic Unit, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
Received 28 January 2013; Revised 21 March 2013; Accepted 11 April 2013
Academic Editor: Nicolaus Kroger
Copyright © 2013 Paola Cordiali-Fei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. Gabrielli, E. V. Avvedimento, and T. Krieg, “Mechanisms of disease: scleroderma,” The New England Journal of Medicine, vol. 360, no. 19, pp. 1989–2003, 2009.
- E. Hachulla and D. Launay, “Diagnosis and classification of systemic sclerosis,” Clinical Reviews in Allergy and Immunology, vol. 40, no. 2, pp. 78–83, 2011.
- E. Carwile LeRoy, C. Black, R. Fleischmajer et al., “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” Journal of Rheumatology, vol. 15, no. 2, pp. 202–205, 1988.
- Y. Hamaguchi, “Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis,” Journal of Dermatology, vol. 37, no. 1, pp. 42–53, 2010.
- Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, “Preliminary criteria for the classification of systemic sclerosis (scleroderma),” Arthritis & Rheumatism, vol. 23, no. 5, pp. 581–590, 1980.
- O. Nadashkevich, P. Davis, and M. J. Fritzler, “A proposal of criteria for the classification of systemic sclerosis,” Medical Science Monitor, vol. 10, no. 11, pp. CR615–CR621, 2004.
- M. Mosca, C. Tani, R. Talarico, and S. Bombardieri, “Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases,” Autoimmunity Reviews, vol. 10, no. 5, pp. 256–258, 2011.
- M. Mosca, C. Tani, and S. Bombardieri, “Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology,” Best Practice and Research, vol. 21, no. 6, pp. 1011–1023, 2007.
- A. Gabrielli, S. Svegliati, G. Moroncini, and E. V. Avvedimento, “Pathogenic autoantibodies in systemic sclerosis,” Current Opinion in Immunology, vol. 19, no. 6, pp. 640–645, 2007.
- M. Kuwana, J. Kaburaki, T. Mimori, Y. Kawakami, and T. Tojo, “Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis 2000,” Arthritis & Rheumatism, vol. 43, no. 5, pp. 1074–1084, 2000.
- T. Y. T. Lu, K. P. Ng, G. Cambridge et al., “A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients,” Arthritis Care and Research, vol. 61, no. 4, pp. 482–487, 2009.
- K. Neubert, S. Meister, K. Moser et al., “The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis,” Nature Medicine, vol. 14, no. 7, pp. 748–755, 2008.
- S. Sakaguchi, M. Miyara, C. M. Costantino, and D. A. Hafler, “FOXP3 + regulatory T cells in the human immune system,” Nature Reviews Immunology, vol. 10, no. 7, pp. 490–500, 2010.
- K. Fujio, T. Okamura, S. Sumitomo, and K. Yamamoto, “Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity,” Annals of the Rheumatic Diseases, vol. 72, pp. ii85–ii89, 2013.
- S. Huber, N. Gagliani, E. Esplugues et al., “Th17 cells express IL-10 receptor and are controlled by Foxp3 and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner,” Immunity, vol. 34, no. 4, pp. 554–565, 2011.
- A. Chaudhry, D. Rudra, P. Treuting et al., “CD4+ regulatory T cells control TH17 responses in a stat3-dependent manner,” Science, vol. 326, no. 5955, pp. 986–991, 2009.
- L. Cederbom, H. Hall, and F. Ivars, “CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells,” European Journal of Immunology, vol. 30, pp. 1538–1543, 2000.
- S. Mehra, J. Walker, K. Patterson, and M. J. Fritzler, “Autoantibodies in systemic sclerosis,” Autoimmunity Reviews, vol. 12, pp. 340–354, 2013.
- D. E. Furst, P. J. Clements, V. D. Steen et al., “The modified rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis,” Journal of Rheumatology, vol. 25, no. 1, pp. 84–88, 1998.
- E. C. LeRoy and T. A. Medsger Jr., “Criteria for the classification of early systemic sclerosis,” Journal of Rheumatology, vol. 28, no. 7, pp. 1573–1576, 2001.
- A. Balbir-Gurman and Y. Braun-Moscovici, “Scleroderma overlap syndrome,” Israel Medical Association Journal, vol. 13, no. 1, pp. 14–20, 2011.
- U. A. Walker, A. Tyndall, L. Czirják, et al., “Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database,” Annals of the Rheumatic Diseases, vol. 66, pp. 754–763, 2007.
- I. N. Targoff, A. E. Johnson, and F. W. Miller, “Antibody to signal recognition particle in polymyositis,” Arthritis & Rheumatism, vol. 33, no. 9, pp. 1361–1370, 1990.
- A. H. Kao, D. Lacomis, M. Lucas, N. Fertig, and C. V. Oddis, “Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy,” Arthritis & Rheumatism, vol. 50, no. 1, pp. 209–215, 2004.
- M. C. Tamby, Y. Chanseaud, L. Guillevin, and L. Mouthon, “New insights into the pathogenesis of systemic sclerosis,” Autoimmunity Reviews, vol. 2, no. 3, pp. 152–157, 2003.
- Y. Mimura, H. Ihn, M. Jinnin, Y. Asano, K. Yamane, and K. Tamaki, “Clinical and laboratory features of scleroderma patients developing skeletal myopathy,” Clinical Rheumatology, vol. 24, no. 2, pp. 99–102, 2005.
- B. Ranque, F. J. Authier, V. Le-Guern et al., “A descriptive and prognostic study of systemic sclerosis-associated myopathies,” Annals of the Rheumatic Diseases, vol. 68, no. 9, pp. 1474–1477, 2009.
- S. Partovi, A. C. Schulte, M. Aschwanden, et al., “Impaired skeletal muscle microcirculation in systemic sclerosis,” Arthritis Research & Therapy, vol. 14, no. 5, article R209, 2012.
- E. Katzap, M. L. Barilla-Labarca, and G. Marder, “Antisynthetase syndrome,” Current Rheumatology Reports, vol. 13, no. 3, pp. 175–181, 2011.
- M. Kalluri, S. A. Sahn, C. V. Oddis et al., “Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature,” Chest, vol. 135, no. 6, pp. 1550–1556, 2009.
- R. W. Koschik, N. Fertig, M. R. Lucas, R. T. Domsic, and T. A. Medsger Jr., “Anti-PM-Scl antibody in patients with systemic sclerosis,” Clinical and Experimental Rheumatology, vol. 30, no. 2, supplement 71, pp. s12–s16, 2012.
- J. L. Sargent and M. L. Whitfield, “Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling,” Expert Review of Clinical Immunology, vol. 7, no. 4, pp. 463–473, 2011.
- R. S. Wildin, S. Smyk-Pearson, and A. H. Filipovich, “Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome,” Journal of Medical Genetics, vol. 39, no. 8, pp. 537–545, 2002.
- E. Antiga, P. Quaglino, S. Bellandi et al., “Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea,” British Journal of Dermatology, vol. 162, no. 5, pp. 1056–1063, 2010.
- M. R. Jocea, M. van Amelsfort, G. J. Walter, and L. S. Taams, “CD4+CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases,” Expert Review of Clinical Immunology, vol. 7, no. 4, pp. 499–514, 2011.
- D. Fenoglio, F. Battaglia, A. Parodi et al., “Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis,” Clinical Immunology, vol. 139, no. 3, pp. 249–257, 2011.
- A. Giovannetti, E. Rosato, C. Renzi et al., “Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes,” Clinical Immunology, vol. 137, no. 1, pp. 122–133, 2010.
- G. Slobodin, M. S. Ahmad, I. Rosner et al., “Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity,” Cellular Immunology, vol. 261, no. 2, pp. 77–80, 2010.
- T. R. D. J. Radstake, L. van Bon, J. Broen et al., “Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression,” PLoS ONE, vol. 4, no. 6, Article ID e5981, 2009.
- T. R. Katsumoto, M. L. Whitfield, and M. K. Connolly, “The pathogenesis of systemic sclerosis,” Annual Review of Pathology, vol. 6, pp. 509–537, 2011.
- M. Hasegawa and K. Takehara, “Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines,” Seminars in Arthritis and Rheumatism, vol. 42, pp. 281–296, 2012.